Search

Your search keyword '"Bourdin, Arnaud"' showing total 546 results
Start Over Author "Bourdin, Arnaud" Search Limiters Full Text
546 results on '"Bourdin, Arnaud"'

2. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.

Author

Maher, Toby, Bourdin, Arnaud, Volkmann, Elizabeth, Vettori, Serena, Distler, Jörg, Alves, Margarida, Stock, Christian, and Distler, Oliver

Subjects
Connective tissue diseases, Pulmonary fibrosis, Scleroderma, systemic, Vital capacity, Humans, Lung, Lung Diseases, Interstitial, Scleroderma, Systemic, Vital Capacity
Abstract

BACKGROUND: The forced vital capacity (FVC) of healthy individuals depends on their age, sex, ethnicity and height. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is characterised by loss of FVC. We compared FVC values in the subjects with SSc-ILD in the SENSCIS trial of nintedanib versus placebo with values from hypothetical matched healthy references. METHODS: The SENSCIS trial enrolled subjects with SSc with first non-Raynaud symptom in the prior ≤ 7 years, extent of fibrotic ILD on HRCT ≥ 10%, and FVC ≥ 40% predicted. FVC at baseline and decline in FVC over 52 weeks were compared with FVC values in hypothetical healthy reference subjects matched 1:1 to the subjects in the trial for age, sex, ethnicity and height, determined using equations published by the European Respiratory Society Global Lung Function Initiative. RESULTS: At baseline, mean (SD) FVC was 2460 (737) mL in the nintedanib group (n = 287) compared with 3403 (787) mL in the hypothetical matched healthy references. Mean (SD) FVC was 2544 (817) mL in the placebo group (n = 286) compared with 3516 (887) mL in the hypothetical matched healthy references. Mean (SE) changes in FVC at week 52, i.e., age-related loss of lung function, in the hypothetical healthy references matched to the nintedanib and placebo groups, respectively, were - 26.3 (0.5) mL and - 25.8 (0.5) mL. The difference in the change in FVC at week 52 between the nintedanib group and the hypothetical healthy references was 26.6 mL (95% CI: 1.2, 52.0; p = 0.04). The difference in the change in FVC at week 52 between the placebo group and the hypothetical healthy references was 77.5 mL (95% CI: 51.4, 103.7; p

Published
2022

5. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial

Author

White, R James, Jerjes-Sanchez, Carlos, Bohns Meyer, Gisela Martina, Pulido, Tomas, Sepulveda, Pablo, Wang, Kuo Yang, Grünig, Ekkehard, Hiremath, Shirish, Yu, Zaixin, Gangcheng, Zhang, Yip, Wei Luen James, Zhang, Shuyang, Khan, Akram, Deng, CQ, Grover, Rob, Tapson, Victor F, Svetliza, Graciela Noemi, Lescano, Adrian Jose, Bortman, Guillermo Roberto, Diez, Fabian Antonio, Botta, Christian Edgardo, Fitzgerald, John, Feenstra, Eelke, Kermeen, Fiona Dawn, Keogh, Anne Margaret, Williams, Trevor John, Yousseff, Peter Paul, Ng, Benjamin Joh-Han, Smallwood, David McNaughton, Dwyer, Nathan Brent, Brown, Martin Russell, Lang, Irene M, Steringer-Mascherbauer, Regina, Arakaki, Jaquelina Sonoe Ota, Campos, Frederico Thadeu Assis Figueiredo, de Amorim Correa, Ricardo, de Souza, Rogerio, Bohns Meyer, Gisela M, Moreira, Maria Auxiliadora Carmo, Yoo, Hugo Hyung Bok, Lapa, Monica Silveira, Swiston, John, Hirani, Naushad, Mehta, Sanjay, Michelakis, Evangelos, Sepulveda, Pablo Andres, Blancaire, Monica Maria Zagolin, Liu, Jimming, Shuyang, Zhang, Pan, Lei, Chunde, Bao, Qun, Yi, Xiaoshu, Cheng, Zaixin, Yu, Li, Xinli, Hua, Yao, Zhu, Xianyang, Chen, Yundai, Zhaozhong, Cheng, Yang, Yuanhua, Daxin, Zhou, Jieyan, Shen, Nielsen-Kudsk, Jens Erik, Carlsen, Jorn, Bourdin, Arnaud, Hachulla, Eric, Dromer, Claire, Chaouat, Ari, Reynaud-Gauber, Martine, Seronde, Marie-France, Klose, Hans, Halank, Michael, Hoffken, Gert, Ewert, Ralf, Rosenkranz, Stephan, Grunig, Ekkehard, Kruger, Ulrich, Kronsbein, Juliane, Hauptmeier, Barbara Monika, Koch, Andrea, Held, Matthias, Lange, Tobias Johannes, Neurohr, Claus, Wilkens, Heinrike, Wilhelm Wirtz, Hubert Rolf, Konstantinides, Stavros, Argyropoulou-Pataka, Paraskevi, Orfanos, Stylianos, Kerkar, Prafulla Gopinath, Suresh, Pujar Venkateshacharya, Baxi, Hemang Ashwinkumar, Oomman, Abraham, Abhaichand, Rajpal Kanaklal, Arjun, Padma Kumar Edla, Chopra, Vijay, Mehrotra, Rahul, Rajput, Rajeev Kumar, and Sawhney, Jitendra Pal Singh

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Clinical Trials and Supportive Activities, Rare Diseases, Patient Safety, Digestive Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Administration, Oral, Adolescent, Adult, Aged, Antihypertensive Agents, Double-Blind Method, Epoprostenol, Female, Humans, Male, Middle Aged, Placebos, Pulmonary Arterial Hypertension, Young Adult, FREEDOM-EV Investigators, clinical study, combination therapy, oral treprostinil, pulmonary arterial hypertension, sequential therapy, Medical and Health Sciences, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk distance 150 m or greater. The primary endpoint was the time to first adjudicated clinical worsening event: death; hospitalization due to worsening PAH; initiation of inhaled or parenteral prostacyclin therapy; disease progression; or unsatisfactory long-term clinical response.Measurements and Main Results: Clinical worsening occurred in 26% of the oral treprostinil group compared with 36% of placebo participants (hazard ratio, 0.74; 95% confidence interval, 0.56-0.97; P = 0.028). Key measures of disease status, including functional class, Borg dyspnea score, and N-terminal pro-brain natriuretic peptide, all favored oral treprostinil treatment at Week 24 and beyond. A noninvasive risk stratification analysis demonstrated that oral treprostinil-assigned participants had a substantially higher mortality risk at baseline but achieved a lower risk profile from Study Weeks 12-60. The most common adverse events in the oral treprostinil group were headache, diarrhea, flushing, nausea, and vomiting.Conclusions: In participants with PAH, addition of oral treprostinil to approved oral monotherapy reduced the risk of clinical worsening.Clinical trial registered with www.clinicaltrials.gov (NCT01560624).

Published
2020

8. Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension

Author

Guignabert, Christophe, Savale, Laurent, Boucly, Athénaïs, Thuillet, Raphaël, Tu, Ly, Ottaviani, Mina, Rhodes, Christopher J., De Groote, Pascal, Prévot, Grégoire, Bergot, Emmanuel, Bourdin, Arnaud, Howard, Luke S., Fadel, Elie, Beurnier, Antoine, Roche, Anne, Jevnikar, Mitja, Jaïs, Xavier, Montani, David, Wilkins, Martin R., Sitbon, Olivier, and Humbert, Marc

Published
2023
Full Text
View/download PDF

9. iPSCs derived from infertile men carrying complex genetic abnormalities can generate primordial germ-like cells

Author

Mouka, Aurélie, Arkoun, Brahim, Moison, Pauline, Drévillon, Loïc, Jarray, Rafika, Brisset, Sophie, Mayeur, Anne, Bouligand, Jérôme, Boland-Auge, Anne, Deleuze, Jean-François, Yates, Frank, Lemonnier, Thomas, Callier, Patrick, Duffourd, Yannis, Nitschke, Patrick, Ollivier, Emmanuelle, Bourdin, Arnaud, De Vos, John, Livera, Gabriel, Tachdjian, Gérard, Maouche-Chrétien, Leïla, and Tosca, Lucie

Published
2022
Full Text
View/download PDF

12. CRISPR/Cas9-mediated gene knockout and interallelic gene conversion in human induced pluripotent stem cells using non-integrative bacteriophage-chimeric retrovirus-like particles

Author

Mianné, Joffrey, Nasri, Amel, Van, Chloé Nguyen, Bourguignon, Chloé, Fieldès, Mathieu, Ahmed, Engi, Duthoit, Christine, Martin, Nicolas, Parrinello, Hugues, Louis, Anaïs, Iché, Alexandra, Gayon, Régis, Samain, Florine, Lamouroux, Lucille, Bouillé, Pascale, Bourdin, Arnaud, Assou, Said, and De Vos, John

Published
2022
Full Text
View/download PDF

14. Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional Analysis

Author

Menzies-Gow, Andrew, primary, Tran, Trung, additional, Stanley, Brooklyn, additional, Carter, Victoria, additional, Smolen, Josef, additional, Bourdin, Arnaud, additional, Fitzgerald, J, additional, Raine, Tim, additional, Chapaneri, Jatin, additional, Emmanuel, Benjamin, additional, Jackson, David, additional, and Price, David, additional

Published
2024
Full Text
View/download PDF

15. Severe asthma care trajectories: the French RAMSES cohort

Author

Perotin, Jeanne-Marie, primary, Gauquelin, Lisa, additional, Just, Nicolas, additional, Devouassoux, Gilles, additional, Chenivesse, Cécile, additional, Bourdin, Arnaud, additional, Garcia, Gilles, additional, Raymond, Christel Saint, additional, Boudjemaa, Amel, additional, Bonniaud, Philippe, additional, Chanez, Pascal, additional, Barnig, Cindy, additional, Beurnier, Antoine, additional, Maurer, Cyril, additional, Freymond, Nathalie, additional, Didi, Toufik, additional, Tcherakian, Colas, additional, Russier, Maud, additional, Drucbert, Mélanie, additional, Guillo, Sylvie, additional, Estellat, Candice, additional, and Taillé, Camille, additional

Published
2024
Full Text
View/download PDF

16. Longitudinal patterns of intermittent oral corticosteroid use for asthma in the UK

Author

Tran, Trung N., primary, Heatley, Heath, additional, Rowell, Jennifer, additional, Kai Chan, Jeffrey Shi, additional, Bourdin, Arnaud, additional, Chapaneri, Jatin, additional, Emmanuel, Benjamin, additional, Gibson, Danny, additional, Jackson, David J., additional, Menzies-Gow, Andrew N., additional, Murray, Ruth, additional, Skinner, Derek, additional, and Price, David, additional

Published
2024
Full Text
View/download PDF

18. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC

Author

Israel-Biet, Dominique, Pison, Christophe, Moro-Sibilot, Denis, Lantuejoul, Sylvie, Stephanov, Olivier, Juliette, Meyzenc, Mendozat, Christophe, Zaidi, Manel, Coulouvrat, Sandra, Col, Edwige, Chanez, Pascal, Greillier, Laurent, Tomasini, Pascale, Barlesi, Fabrice, Mascaux, Céline, Jourdan, Sandrine, Roger, Aurélie, Biemar, Julie, Randriamampionona, Rondro, Chabot, François, Tiotiu, Angélica, Clement-Duchene, Christelle, Vignaud, Jean-Michel, Lacomme, Stéphanie, Lomazzi, Sandra, Laurent, Carine, Bulsei, Xavier, Bischoff, Laura, Rakotonirina, Raymond, Layouni, Mehdi, Deslee, Gaëtan, Mal, Hervé, Kessler, Romain, Vergnon, Jean-Michel, Pelissier, Isabelle, Cuvelier, Antoine, Bourdin, Arnaud, Jounieaux, Vincent, Roche, Nicolas, Jouneau, Stéphane, Bonniaud, Philippe, Scherpereel, Arnaud, Mornex, Jean François, Steenhouwer, François, Leroy, Sylvie, Marquette, Charles Hugo, Benzaquen, Jonathan, Mazzette, Andrea, Padovani, Bernard, Hofman, Paul, Ilié, Marius, Hofman, Véronique, Fayada, Julien, Long-Mira, Elodie, Lassalle, Sandra, Pradelli, Johanna, Martinez, Estelle, Habault, Marine, Bonnard, Mélanie, Moutarde, Julie, Yatimi, Rachida, Labsi, Hakima, Gazoppi, Loïc, Lpce, Tumorothèque, Griffonnet, Jennifer, Fontaine, Maureen, Guillemart, Ariane, Butori, Catherine, Selva, Eric, Poudenx, Michel, Otto, Josiane, Hebert, Christophe, Botchiellini, Delphine, Boudouf, Soukaina, Menier, Margaux, Occeli, Estelle, Bellentani, Sophie, Pion, Carine, Fournier, Elodie, Thariat, Juliette, Gervais, Radj, Hamond, Karim, Marchand-Adam, Sylvain, Plantier, Laurent, Fajolle, Gaelle, Rayez, Mélanie, Cadranel, Jacques, Fallet, Vincent, Wislez, Marie, Antoine, Martine, Cote, Jean-François, Chaabane, Nouha, Ruppert, Anne Marie, Bertrand, Eliane, Rodenas, Anita, Pontdeme, Gwenaëlle, Mathiot, Nathalie, Ribert, Tamazouzt, Mazières, Julien, Guibert, Nicolas, Rouviere, Damien, Bousquet, Emilie, Bigay-Game, Laurence, Hermant, Christophe, Plat, Gavin, Rouquette, Isabelle, Evrard, Solène, Gouin, Sandrine, Clermont, Estelle Taranchon, Dormoy, Inge, Coulomb, Christelle, Pradine, Anne, Lambert, Véronique, Laborde, Lilian, Castelnau, Olivier, Chamorey, Emmanuel, Heeke, Simon, Thamphya, Brice, Boutros, Jacques, Clément-Duchêne, Christelle, and Marquette, Charles-Hugo

Published
2021
Full Text
View/download PDF

20. Healthcare Resource Utilization Associated with Intermittent Oral Corticosteroid Prescribing Patterns in Asthma.

Author

Tran, Trung N, Heatley, Heath, Bourdin, Arnaud, Menzies-Gow, Andrew, Jackson, David J, Maslova, Ekaterina, Chapaneri, Jatin, Henley, William, Carter, Victoria, Chan, Jeffrey Shi Kai, Ariti, Cono, Haughney, John, and Price, David

Subjects
LENGTH of stay in hospitals, HOSPITAL statistics, MEDICAL care costs, MEDICAL records, PRIMARY care
Abstract

Purpose: Oral corticosteroid (OCS) use for asthma is associated with considerable healthcare resource utilization (HCRU) and costs. However, no study has investigated this in relation to patterns of intermittent OCS prescription. Methods: This historical UK cohort study used primary care medical records, linked to Hospital Episode Statistics, from 2008 to 2019, of patients (≥ 4 years old) with asthma prescribed intermittent OCS. Patients were categorized by OCS prescribing pattern (one-off [single], less frequent [≥ 90-day gap] and frequent [< 90-day gap]) and matched 1:1 (by sex, age and index date) with people never prescribed OCS with/without asthma. HCRU (reported as episodes, except for length of hospital stay [days] and any prescription [records]) and associated costs were compared between intermittent OCS and non-OCS cohorts, and among intermittent OCS prescribing patterns. Results: Of 149,191 eligible patients, 50.3% had one-off, 27.4% less frequent, and 22.3% frequent intermittent OCS prescribing patterns. Annualized non-respiratory HCRU rates were greater in the intermittent OCS versus non-OCS cohorts for GP visits (5.93 vs 4.70 episodes, p < 0.0001), hospital admissions (0.24 vs 0.16 episodes, p < 0.0001), and length of stay (1.87 vs 1.58 days, p < 0.0001). In the intermittent OCS cohort, rates were highest in the frequent prescribing group for GP visits (7.49 episodes; p < 0.0001 vs one-off), length of stay (2.15 days; p < 0.0001) and any prescription including OCS (25.22 prescriptions; p < 0.0001). Mean per-patient non-respiratory related and all-cause HCRU-related costs were higher with intermittent OCS than no OCS (£ 3902 vs £ 2722 and £ 8623 vs £ 4929, respectively), as were mean annualized costs (£ 565 vs £ 313 and £ 1526 vs £ 634, respectively). A dose–response relationship existed; HCRU-related costs were highest in the frequent prescribing cohort (p < 0.0001). Conclusion: Intermittent OCS use and more frequent intermittent OCS prescription patterns were associated with increased HCRU and associated costs. Improved asthma management is needed to reduce reliance on intermittent OCS in primary care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Adult Severe Asthma Registries: A Global and Growing Inventory

Author

Cushen, Breda, primary, Koh, Mariko Siyue, additional, Tran, Trung N, additional, Martin, Neil, additional, Murray, Ruth, additional, Uthaman, Thendral, additional, Goh, Celine Yun Yi, additional, Vella, Rebecca, additional, Eleangovan, Neva, additional, Bulathsinhala, Lakmini, additional, Maspero, Jorge, additional, Peters, Matthew, additional, Schleich, Florence, additional, Pitrez, Paulo, additional, Christoff, George, additional, Sadatsafavi, Mohsen, additional, Torres-Duque, Carlos A, additional, Porsbjerg, Celeste, additional, Altraja, Alan, additional, Lehtimäki, Lauri, additional, Bourdin, Arnaud, additional, Taube, Christian, additional, Papadopoulos, Nikolaos G, additional, Zsuzsanna, Csoma, additional, Björnsdóttir, Unnur, additional, Salvi, Sundeep, additional, Heffler, Enrico, additional, Iwanaga, Takashi, additional, al-Ahmad, Mona, additional, Larenas-Linnemann, Désirée, additional, van Boven, Job FM, additional, Aarli, Bernt Bøgvald, additional, Kuna, Piotr, additional, Loureiro, Cláudia Chaves, additional, Al-lehebi, Riyad, additional, Lee, Jae Ha, additional, Marina, Nuria, additional, Bjermer, Leif, additional, Sheu, Chau-Chyun, additional, Mahboub, Bassam, additional, Busby, John, additional, Menzies-Gow, Andrew, additional, Wang, Eileen, additional, and Price, David, additional

Published
2023
Full Text
View/download PDF

26. Outcomes and risk assessment in pulmonary veno-occlusive disease.

Author

Boucly, Athénaïs, Solinas, Sabina, Beurnier, Antoine, Jaïs, Xavier, Keddache, Sophia, Eyries, Mélanie, Seferian, Andrei, Jevnikar, Mitja, Roche, Anne, Bulifon, Sophie, Bourdin, Arnaud, Chaouat, Ari, Cottin, Vincent, Bertoletti, Laurent, Savale, Laurent, Humbert, Marc, Sitbon, Olivier, and Montani, David

Published
2024
Full Text
View/download PDF

29. The Transcriptome Landscape of the In Vitro Human Airway Epithelium Response to SARS-CoV-2

Author

Assou, Said, primary, Ahmed, Engi, additional, Morichon, Lisa, additional, Nasri, Amel, additional, Foisset, Florent, additional, Bourdais, Carine, additional, Gros, Nathalie, additional, Tieo, Sonia, additional, Petit, Aurelie, additional, Vachier, Isabelle, additional, Muriaux, Delphine, additional, Bourdin, Arnaud, additional, and De Vos, John, additional

Published
2023
Full Text
View/download PDF

32. Diastolic Cardiomyopathy Secondary to Experimentally Induced Exacerbated Emphysema

Author

Grillet, Pierre-Edouard, primary, Desplanche, Elodie, additional, Wynands, Quentin, additional, Gouzi, Fares, additional, Bideaux, Patrice, additional, Fort, Aurelie, additional, Scheuermann, Valérie, additional, Lacampagne, Alain, additional, Virsolvy, Anne, additional, Thireau, Jérôme, additional, de Tombe, Pieter, additional, Bourdin, Arnaud, additional, and Cazorla, Olivier, additional

Published
2023
Full Text
View/download PDF

35. International severe asthma registry (ISAR): protocol for a global registry

Author

FitzGerald, J. Mark, Tran, Trung N., Alacqua, Marianna, Altraja, Alan, Backer, Vibeke, Bjermer, Leif, Bjornsdottir, Unnur, Bourdin, Arnaud, Brusselle, Guy, Bulathsinhala, Lakmini, Busby, John, Canonica, Giorgio W., Carter, Victoria, Chaudhry, Isha, Cho, You Sook, Christoff, George, Cosio, Borja G., Costello, Richard W., Eleangovan, Neva, Gibson, Peter G., Heaney, Liam G., Heffler, Enrico, Hew, Mark, Hosseini, Naeimeh, Iwanaga, Takashi, Jackson, David J., Jones, Rupert, Koh, Mariko S., Le, Thao, Lehtimäki, Lauri, Ludviksdottir, Dora, Maitland-van der Zee, Anke H., Menzies-Gow, Andrew, Murray, Ruth B., Papadopoulos, Nikolaos G., Perez-de-Llano, Luis, Peters, Matthew, Pfeffer, Paul E., Popov, Todor A., Porsbjerg, Celeste M., Price, Chris A., Rhee, Chin K., Sadatsafavi, Mohsen, Tohda, Yuji, Wang, Eileen, Wechsler, Michael E., Zangrilli, James, and Price, David B.

Published
2020
Full Text
View/download PDF

38. Evaluation of Real-World Mepolizumab Use in Severe Asthma across Europe - the SHARP experience with privacy-preserving federated analysis

Author

Kroes, Johannes A., primary, Alfonso-Cristancho, Rafael, additional, Bansal, Aruna T., additional, Berret, Emmanuelle, additional, Bieksiene, Kristina, additional, Bourdin, Arnaud, additional, Brussino, Luisa, additional, Canhoto, Diogo, additional, Cardini, Cristina, additional, Celik, Gulfem, additional, Csoma, Zsuzsanna, additional, Dahlén, Barbro, additional, Damadoglu, Ebru, additional, Eger, Katrien, additional, Gauquelin, Lisa, additional, Gemicioglu, Bilun, additional, Goksel, Ozlem, additional, Graff, Sophie, additional, Heffler, Enrico, additional, Hofstee, Hendrik B., additional, Howarth, Peter, additional, Jakes, Rupert W., additional, Jaun, Fabienne, additional, Kalinauskaite-Zukauske, Virginija, additional, Kopač, Peter, additional, Kwon, Namhee, additional, Loureiro, Claudia C., additional, Lozoya García, Victor, additional, Masoli, Matthew, additional, Paula Rezelj, Mariana, additional, De Llano, Luis Pérez, additional, Popović-Grle, Sanja, additional, Ramos-Barbon, David, additional, Sà Sousa, Ana, additional, Samitas, Konstantinos, additional, Schleich, Florence, additional, Sirena, Concetta, additional, Skrgat, Sabina, additional, Zervas, Eleftherios, additional, Zichnalis, George, additional, Bel, Elisabeth H., additional, Sont, Jacob K., additional, Hashimoto, Simone, additional, and Ten Brinke, Anneke, additional

Published
2023
Full Text
View/download PDF

39. Sputum-Rheology-Based Strategy for Guiding Azithromycin Prescription in COPD Patients with Frequent Exacerbations: A Randomized, Controlled Study (“COPD CARhE”)

Author

Charriot, Jeremy, primary, Maeva, Zysman, additional, Guilleminault, Laurent, additional, Volpato, Mathilde, additional, Fort-Petit, Aurelie, additional, Vachier, Isabelle, additional, Patarin, Jeremy, additional, Suehs, Carey, additional, Engi, Ahmed, additional, Molinari, Nicolas, additional, and Bourdin, Arnaud, additional

Published
2023
Full Text
View/download PDF

40. In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicentre study

Author

Chaigne, Benjamin, primary, Chevalier, Kevin, additional, Boucly, Athenaïs, additional, Agard, Christian, additional, Baudet, Antoine, additional, Bourdin, Arnaud, additional, Chabanne, Céline, additional, Cottin, Vincent, additional, Fesler, Pierre, additional, Goupil, François, additional, Jego, Patrick, additional, Launay, David, additional, Lévesque, Hervé, additional, Maurac, Arnaud, additional, Mohamed, Shirine, additional, Tromeur, Cécile, additional, Rottat, Laurence, additional, Sitbon, Olivier, additional, Humbert, Marc, additional, and Mouthon, Luc, additional

Published
2023
Full Text
View/download PDF

42. Definitions of non-response and response to biological therapy for severe asthma: a systematic review

Author

Khaleva, Ekaterina, primary, Rattu, Anna, additional, Brightling, Chris, additional, Bush, Andrew, additional, Bourdin, Arnaud, additional, Bossios, Apostolos, additional, Chung, Kian Fan, additional, Chaudhuri, Rekha, additional, Coleman, Courtney, additional, Djukanovic, Ratko, additional, Dahlén, Sven-Erik, additional, Exley, Andrew, additional, Fleming, Louise, additional, Fowler, Stephen J., additional, Gupta, Atul, additional, Hamelmann, Eckard, additional, Koppelman, Gerard H., additional, Melén, Erik, additional, Mahler, Vera, additional, Seddon, Paul, additional, Singer, Florian, additional, Porsbjerg, Celeste, additional, Ramiconi, Valeria, additional, Rusconi, Franca, additional, Yasinska, Valentyna, additional, and Roberts, Graham, additional

Published
2023
Full Text
View/download PDF

43. Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study

Author

Guilleminault, Laurent, primary, Camus, Claire, additional, Raherison-Semjen, Chantal, additional, Capdepon, Audrey, additional, Bourdin, Arnaud, additional, Bonniaud, Philippe, additional, Fry, Stéphanie, additional, Devouassoux, Gilles, additional, Blanc, François-Xavier, additional, Pison, Christophe, additional, Dupin, Clairelyne, additional, Khayath, Naji, additional, Courdeau, Joelle, additional, Valcke-Brossollet, Judith, additional, Nocent-Ejnaini, Cécilia, additional, Rolland, Fabien, additional, Lamandi, Carmen, additional, Proust, Alain, additional, Ozier, Anaig, additional, Portel, Laurent, additional, Gaspard, Wanda, additional, Roux-Claude, Pauline, additional, Beurnier, Antoine, additional, Martinez, Stéphanie, additional, Dot, Jean-Marc, additional, Hennegrave, Florence, additional, Vignal, Guillaume, additional, Auvray, Etienne, additional, Paleiron, Nicolas, additional, Just, Nicolas, additional, Miltgen, Jean, additional, Russier, Maud, additional, Olivier, Cécile, additional, Taillé, Camille, additional, and Didier, Alain, additional

Published
2023
Full Text
View/download PDF

46. Identifying and appraising outcome measures for severe asthma: a systematic review

Author

Rattu, Anna, primary, Khaleva, Ekaterina, additional, Brightling, Chris, additional, Dahlén, Sven-Erik, additional, Bossios, Apostolos, additional, Fleming, Louise, additional, Chung, Kian Fan, additional, Melén, Erik, additional, Djukanovic, Ratko, additional, Chaudhuri, Rekha, additional, Exley, Andrew, additional, Koppelman, Gerard H., additional, Bourdin, Arnaud, additional, Rusconi, Franca, additional, Porsbjerg, Celeste, additional, Coleman, Courtney, additional, Williams, Clare, additional, Nielsen, Hanna, additional, Davin, Elizabeth, additional, Taverner, Phil, additional, Romagosa Vilarnau, Sofia, additional, and Roberts, Graham, additional

Published
2022
Full Text
View/download PDF

47. Cytokines as prognostic biomarkers in pulmonary arterial hypertension

Author

Boucly, Athénaïs, primary, Tu, Ly, additional, Guignabert, Christophe, additional, Rhodes, Christopher, additional, De Groote, Pascal, additional, Prévot, Grégoire, additional, Bergot, Emmanuel, additional, Bourdin, Arnaud, additional, Beurnier, Antoine, additional, Roche, Anne, additional, Jevnikar, Mitja, additional, Jaïs, Xavier, additional, Montani, David, additional, Wilkins, Martin R., additional, Humbert, Marc, additional, Sitbon, Olivier, additional, and Savale, Laurent, additional

Published
2022
Full Text
View/download PDF

50. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)

Author

Khaleva, Ekaterina, primary, Rattu, Anna, additional, Brightling, Chris, additional, Bush, Andrew, additional, Bossios, Apostolos, additional, Bourdin, Arnaud, additional, Chung, Kian Fan, additional, Chaudhuri, Rekha, additional, Coleman, Courtney, additional, Dahlén, Sven-Erik, additional, Djukanovic, Ratko, additional, Deschildre, Antoine, additional, Fleming, Louise, additional, Fowler, Stephen J., additional, Gupta, Atul, additional, Hamelmann, Eckard, additional, Hashimoto, Simone, additional, Hedlin, Gunilla, additional, Koppelman, Gerard H., additional, Melén, Erik, additional, Murray, Clare S., additional, Pilette, Charles, additional, Porsbjerg, Celeste, additional, Pike, Katharine C., additional, Rusconi, Franca, additional, Williams, Clare, additional, Ahrens, Birgit, additional, Alter, Peter, additional, Anckers, Freja, additional, van den Berge, Maarten, additional, Blumchen, Katharina, additional, Brusselle, Guy, additional, Clarke, Graham W., additional, Cunoosamy, Danen, additional, Dahlén, Barbro, additional, Dixey, Piers, additional, Exley, Andrew, additional, Frey, Urs, additional, Gaillard, Erol A., additional, Giovannini-Chami, Lisa, additional, Grigg, Jonathan, additional, Hartenstein, Diana, additional, Heaney, Liam G., additional, Karadag, Bülent, additional, Kaul, Susanne, additional, Kull, Inger, additional, Licari, Amelia, additional, Maitland-van der Zee, Anke H., additional, Mahler, Vera, additional, Schoos, Ann-Marie M., additional, Nagakumar, Prasad, additional, Negus, Jenny, additional, Nielsen, Hanna, additional, Paton, James, additional, Pijnenburg, Mariëlle, additional, Ramiconi, Valeria, additional, Romagosa Vilarnau, Sofia, additional, Principe, Stefania, additional, Rutjes, Niels, additional, Saglani, Sejal, additional, Seddon, Paul, additional, Singer, Florian, additional, Staudinger, Heribert, additional, Turner, Steve, additional, Vijverberg, Susanne, additional, Winders, Tonya, additional, Yasinska, Valentyna, additional, and Roberts, Graham, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results